Invivo Partners participates in the €11.1 million Seed extension round of Signadori Bio alongside Taiho Ventures and Sofinnova Partners

by Invivo Capital

Signadori Bio focuses on directly engineering monocytes in vivo to reprogram myeloid anti-tumour activity, aiming to overcome the immunosuppressive tumour microenvironment and unlock a new class of of...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Alantra advises Precinmac on its acquisi...

by Alantra

This transaction reinforces Alantra’s continued momentum in Aerospac...

Photos Stream